Optimizing antigen selection for the development of tuberculosis vaccines
Tuberculosis (TB) remains a prevalent global infectious disease caused by genetically closely related tubercle bacilli in Mycobacterium tuberculosis complex (MTBC). For a century, the Bacillus Calmette-Guérin (BCG) vaccine has been the primary preventive measure against TB. While it effectively prot...
Main Authors: | Yang Yang, Yi-Zhen Chen, Tian Xia |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2024-06-01
|
Series: | Cell Insight |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S277289272400018X |
Similar Items
-
In silico design of a promiscuous chimeric multi-epitope vaccine against Mycobacterium tuberculosis
by: Binda T. Andongma, et al.
Published: (2023-01-01) -
A phase I, open-label trial on the safety and immunogenicity of the adjuvanted tuberculosis subunit vaccine H1/IC31® in people living in a TB-endemic area
by: Jemal Hussein, et al.
Published: (2018-01-01) -
Adjuvants and Antigen-Delivery Systems for Subunit Vaccines against Tuberculosis
by: Abu Salim Mustafa
Published: (2021-08-01) -
Identification and evaluation of the novel immunodominant antigen Rv2351c from Mycobacterium tuberculosis
by: Xuezhi Wang, et al.
Published: (2017-01-01) -
Synthetic carbohydrate-based vaccines: challenges and opportunities
by: Ravinder Mettu, et al.
Published: (2020-01-01)